Adimmune

News

2020-12-30

Adimmune Biotech Corporation(4142) is determined and committed to continue developing the COVID-19 vaccine

Adimmune Biotech Corporation pointed out, after receiving the government's official notification and recommendations on the clinical test, it would move on to  Phase 2 clinical test. Adimmune stressed that the company would continue investing in vaccine development with or without public funding. It is already planning for the Phase 2 and 3 clinical tests domestically and overseas. The company’s commitment in developing and producing the COVID-19 vaccine never changed, and its determination to safeguard public health and regard Taiwan as the first priority for the vaccine stays the same. 

Adimmune was the first corporation to engage in vaccine research and development in the beginning of the outbreak in early 2020. The entire staff worked tirelessly during 2020 and would continue to complete the goals of developing, clinical tests and manufacturing. The company wishes to supply safe and effective vaccines to the general public as soon as possible.